NCT04068610 - COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 13, 2019

Primary Completion Date

October 10, 2022

Study Completion Date

November 24, 2025

Conditions

Metastatic Microsatellite-stable Colorectal Cancer

Interventions

DRUG

Durvalumab

Participants will receive IV infusion of durvalumab as stated in arm description.

DRUG

Oleclumab

Participants will receive IV infusion of oleclumab as stated in arm description.

DRUG

FOLFOX

Participants will receive IV infusion of FOLFOX (5-FU, oxaliplatin, and folinic acid) as stated in arm description.

DRUG

Bevacizumab

Participants will receive IV infusion of bevacizumab as stated in arm description.

Trial Locations (21)

3000

Research Site, Melbourne

3084

Research Site, Heidelberg

3168

Research Site, Clayton

10065

Research Site, New York

22908

Research Site, Charlottesville

28027

Research Site, Madrid

28046

Research Site, Madrid

37203

Research Site, Nashville

37404

Research Site, Chattanooga

44000

Research Site, Nantes

44718

Research Site, Canton

48109

Research Site, Ann Arbor

77030

Research Site, Houston

89169

Research Site, Las Vegas

90095

Research Site, Los Angeles

94805

Research Site, Villejuif

95817

Research Site, Sacramento

02903

Research Site, Providence

M5G 1X6

Research Site, Toronto

08035

Research Site, Barcelona

08916

Research Site, Barcelona